Search

Your search keyword '"Volker Schellenberger"' showing total 21 results
Start Over "Volker Schellenberger" Journal internet wire
21 results on '"Volker Schellenberger"'

2. Amunix announces broad alliance with Genentech using XTEN(R) technology

Subjects
Research and development, Genentech Inc. -- Research agreements, Roche Holding AG -- Research agreements, Biological products industry -- Research agreements, Biotechnology industry -- Research agreements, Industrial research -- United States -- Switzerland, Pharmaceutical industry -- Research agreements
Abstract

Feb 15, 2017 (Marketwired via COMTEX) -- MOUNTAIN VIEW, CA--(Marketwired - February 15, 2017) - Amunix Operating Inc. (Amunix), a biopharmaceutical company focused on the discovery and development of novel […]

Published
2017

3. Amunix Appoints Fred Hausheer, MD, FACP, as Chief Medical Officer

Subjects
Drug discovery, Business, Business, international, News, opinion and commentary
Abstract

Feb 13, 2017 (Marketwired via COMTEX) -- MOUNTAIN VIEW, CA--(Marketwired - February 13, 2017) - Amunix Operating Inc., a privately held biotechnology company and developer of a broad portfolio of [...]

Published
2017

4. Biogen exercises option to enter into exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN(R) half-life extension technology

Subjects
Hemophilia, Factor IX -- Licensing agreements, Biological products industry -- Licensing agreements, Company licensing agreement, Business, Business, international, News, opinion and commentary
Abstract

Jan 05, 2017 (Marketwired via COMTEX) -- MOUNTAIN VIEW, CA--(Marketwired - January 05, 2017) - Amunix Operating Inc. announced today that Biogen (NASDAQ: BIIB) has exercised its option to enter [...]

Published
2017

5. IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases

Subjects
United States. Food and Drug Administration, Malabsorption syndromes, Clinical trials, Business, Business, international, News, opinion and commentary
Abstract

Dec 19, 2016 (Marketwired via COMTEX) -- MOUNTAIN VIEW, CA--(Marketwired - December 19, 2016) - Amunix is pleased to announce that Naia Rare Diseases, a biopharmaceutical company developing drugs for [...]

Published
2016

6. Phase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN(R) Technology

Subjects
Somatotropin -- Product development -- Technology application, Gene therapy -- Technology application, Technology application, Business, Business, international, News, opinion and commentary
Abstract

Oct 17, 2016 (Marketwired via COMTEX) -- MOUNTAIN VIEW, CA--(Marketwired - October 17, 2016) - Amunix is pleased to announce that Versartis Inc. (NASDAQ: VSAR) has been granted approval in [...]

Published
2016

7. Harold E. 'Barry' Selick, Ph.D. and Walter H. Moos, Ph.D. Join Amunix Board of Directors

Subjects
Protein Design Labs Inc. -- Officials and employees, Boards of directors, Biological products industry -- Officials and employees, Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, Mar 03, 2016 (Marketwired via COMTEX) -- Amunix is pleased to announce the appointment Harold E. 'Barry' Selick and Walter H. Moos to the company's board [...]

Published
2016

8. Amunix Establishes GMP Manufacturing of XTEN(TM) at UN-L BPDF

Subjects
Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, Nov 16, 2015 (Marketwired via COMTEX) -- Amunix Operating Inc. (Amunix), a leader in the area of protein half-life extension, today announced that it has completed [...]

Published
2015

9. Amunix Announces Extension of Evaluation Agreement With Roche

Subjects
Biotechnology industries -- Alliances and partnerships, Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, Oct 26, 2015 (Marketwired via COMTEX) -- Amunix Operating Inc. (Amunix), a leader in the area of protein half-life extension, today announced that its partner Roche [...]

Published
2015

10. Amunix Announces Exclusive Agreements With Naia to Develop GLP-1 and GLP-2 XTEN(TM) Products

Subjects
Diabetes therapy -- Licensing agreements, Company licensing agreement, Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, Jan 05, 2015 (Marketwired via COMTEX) -- Amunix Operating Inc. (Amunix), a leader in the field of protein half-life extension, today announced a research and development [...]

Published
2015

11. Amunix Announces Option Exercise by Eli Lilly and Company for XTEN(TM) Product for People With Diabetes

Subjects
Eli Lilly and Co. -- Research agreements, Diabetes, Diabetics, Pharmaceutical industry -- Research agreements, Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, Dec 17, 2014 (Marketwired via COMTEX) -- Amunix Operating Inc. (Amunix), a leader in the field of protein half-life extension, today announced that its partner Eli [...]

Published
2014

12. Amunix and PolyPeptide Enter Into Partnership to Produce XTEN(TM) Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics

Subjects
Proteins, Pharmaceutical industry -- Alliances and partnerships, Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, Oct 28, 2014 (Marketwired via COMTEX) -- Amunix Operating Inc., and PolyPeptide Laboratories, Inc. (PPL) have entered into a partnership under which Amunix's proprietary recombinantly derived [...]

Published
2014

13. Amunix Signs a Services and Supply Agreement With the University of Nebraska-Lincoln to Produce GMP-Grade XTEN(TM) for Pharmaceutical Therapeutics

Subjects
Proteins, Universities and colleges, Pharmaceutical industry, Business, Business, international, News, opinion and commentary, University of Nebraska-Lincoln
Abstract

Byline: MOUNTAIN VIEW, CA, Oct 27, 2014 (Marketwired via COMTEX) -- Amunix Operating Inc., a biotechnology company developing polypeptides which can be recombinantly fused or chemically conjugated to other peptides, [...]

Published
2014

14. Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal 'Bioconjugate Chemistry'

Subjects
Antiviral agents, Drug approval, Proteins, Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, Jul 23, 2014 (Marketwired via COMTEX) -- Amunix Operating Inc., a biotechnology company developing hydrophilic, unstructured polypeptides which can be recombinantly fused or chemically conjugated to [...]

Published
2014

15. Amunix Congratulates Versartis on Its Positive Phase 2a Results With VRS-317

Subjects
Somatotropin -- Product development -- Technology application, Clinical trials -- Technology application, Proteins -- Technology application, Technology application, Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, Jun 30, 2014 (Marketwired via COMTEX) -- Amunix Operating Inc., a biotechnology company developing a half-life extension technology for peptides, proteins and small molecules, congratulates Versartis, [...]

Published
2014

17. Amunix to Present Unpublished Data at Next Generation Protein Therapeutics Summit

Subjects
Proteins, Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, May 28, 2014 (Marketwired via COMTEX) -- Amunix Operating Inc. today announced the company will present new data from its XTEN half-life extension technology development programs [...]

Published
2014

18. Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII

Subjects
Biological products industry -- Licensing agreements, Blood coagulation factor VIII, Company licensing agreement, Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, Apr 21, 2014 (Marketwired via COMTEX) -- Amunix Operating Inc. announced today that Biogen Idec (NASDAQ: BIIB) has exercised its option to enter into an exclusive, [...]

Published
2014

19. Amunix Announces Expansion to Licensing Agreement With Janssen for Its Proprietary XTEN Technology

Subjects
Biopharmaceutics -- Licensing agreements, Company licensing agreement, Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, Jan 07, 2014 (Marketwired via COMTEX) -- Amunix Operating Inc. (Amunix) announced today that Janssen Biotech, Inc. (Janssen) has expanded its existing worldwide research collaboration and [...]

Published
2014

20. Amunix Announces Update to Licensing Agreement With Janssen for Its Proprietary XTEN Technology

Subjects
Homeopathy -- Materia medica and therapeutics, Biotechnology industry -- Licensing agreements -- Alliances and partnerships, Therapeutics -- Licensing agreements, Company licensing agreement, Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, Aug 14, 2013 (Marketwired via COMTEX) -- Amunix Operating Inc. (Amunix), today announced that an option for an additional product has been exercised under its worldwide [...]

Published
2013

21. Preclinical Data From Biogen Idec-Amunix Partnership Presented at ISTH Congress

Subjects
Biological products industry -- Product development -- Political activity -- Political aspects, Blood coagulation factor VIII -- Political aspects, Business, Business, international, News, opinion and commentary
Abstract

Byline: MOUNTAIN VIEW, CA, Jul 01, 2013 (Marketwired via COMTEX) -- Amunix Operating Inc. (Amunix) announced that the first of five presentations made by Biogen Idec -- featuring preclinical research [...]

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results